COMPANY SPOTLIGHT -- MedImmune.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      MEDIMMUNE Inc.; NOVARTIS AG
    • Abstract:
      The article reports that MedImmune Inc. has licensed its reverse genetics technology to Novartis AG to support the development and construction of new vaccine strains to produce inactivated human seasonal, pre-pandemic and pandemic influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. It has also reported that its RSV drug achieved its goals in a Phase III trial.